Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353⦠read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
$1.65
Price-0.87%
-$0.02
$19.344m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-
3y CAGR-
5y CAGR-$1.043m
-
1y CAGR-
3y CAGR-
5y CAGR-$0.09
-
1y CAGR-
3y CAGR-
5y CAGR$12.593m
$17.370m
Assets$4.777m
Liabilities-
Debt0.00%
-
Debt to EBITDA-$3.217m
-
1y CAGR-
3y CAGR-
5y CAGR